Dyadic International Inc DYAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.74–0.76
- 52-Week Range
- $0.66–1.33
- Bid/Ask
- $0.75 / $0.77
- Shares Outstanding
- 36.44M
- Market Cap
- $26.96M
- Volume/Avg
- 46,039 / 240,487
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.dyadic.com
Valuation
|
Metric
|
DYAI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 13.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DYAI
|
|---|---|
Quick Ratio | 2.08 |
Current Ratio | 2.42 |
Interest Coverage | −15.71 |
Quick Ratio
DYAI
Profitability
|
Metric
|
DYAI
|
|---|---|
Return on Assets (Normalized) | −70.58% |
Return on Equity (Normalized) | −838.63% |
Return on Invested Capital (Normalized) | −106.73% |
Return on Assets
DYAI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Djvzydlsf | Ygbzpk | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zzgfvmwqz | Ztvbsn | $64B | |||
| argenx SE ADR
ARGX
| Plrxngmc | Sgzwg | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Swvsblhh | Fztkkb | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Jnyxhftyl | Yhqjfn | $24B | |||
| BioNTech SE ADR
BNTX
| Pcdhbtcr | Jhcj | $23B | |||
| Incyte Corp
INCY
| Nfjxmmc | Mssv | $22B | |||
| Moderna Inc
MRNA
| Nrflvcs | Rvr | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qsnhjgxbh | Xvgf | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Gytlvgvk | Zngmq | $13B |
United States